Literature DB >> 19198627

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.

A Prasad1, I-W Park, H Allen, X Zhang, M V R Reddy, R Boominathan, E P Reddy, J E Groopman.   

Abstract

Mantle cell lymphoma (MCL) is characterized by the uncontrolled overexpression of cyclin D1. Styryl sulfonyl compounds have shown potent antitumor activity against MCL by inducing cell-cycle arrest and apoptosis. However, the exact molecular mechanism by which these compounds function is yet to be elucidated. Here, we show that the prototypical styryl sulfonyl compound ON 01910.Na decreased cyclin D1 and c-Myc protein levels in MCL cells, whereas mRNA levels of cyclin D1 were minimally affected. Notably, ON 01910.Na suppressed eukaryotic translation initiation factor 4E (eIF4E)-mediated cyclin D1 mRNA translation, decreased levels of phosphorylated Akt, mammalian target of Rapamycin (mTOR) and eIF4E-binding protein (eIF4E-BP), lowered the cap site binding activity of eIF4E and directly inhibited activity of phosphatidylinositol-3 kinase (PI-3K). Analysis of apoptotic signaling pathways revealed that ON 01910.Na induced the release of cytochrome c from mitochondria, altered expression of Bcl-2 family of proteins and stimulated activation of caspases. Taken together, styryl sulfonyls can cause a rapid decrease of cyclin D1 by blocking cyclin D1 mRNA translation through inhibition of the PI-3K/Akt/mTOR/eIF4E-BP signaling pathway and triggering a cytochrome c-dependent apoptotic pathway in MCL cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19198627     DOI: 10.1038/onc.2008.502

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

Review 1.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.

Authors:  Tapan M Kadia; Elias Jabbour; Hagop Kantarjian
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

3.  Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.

Authors:  M V Ramana Reddy; Padmavathi Venkatapuram; Muralidhar R Mallireddigari; Venkat R Pallela; Stephen C Cosenza; Kimberly A Robell; Balaiah Akula; Benjamin S Hoffman; E Premkumar Reddy
Journal:  J Med Chem       Date:  2011-08-17       Impact factor: 7.446

Review 4.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 5.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

6.  A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

Authors:  Brad S Kahl; Stephen E Spurgeon; Richard R Furman; Ian W Flinn; Steven E Coutre; Jennifer R Brown; Don M Benson; John C Byrd; Sissy Peterman; Yoonjin Cho; Albert Yu; Wayne R Godfrey; Nina D Wagner-Johnston
Journal:  Blood       Date:  2014-03-10       Impact factor: 22.113

7.  Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.

Authors:  Lorenzo Agoni; Indranil Basu; Seema Gupta; Alan Alfieri; Angela Gambino; Gary L Goldberg; E Premkumar Reddy; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-11       Impact factor: 7.038

Review 8.  Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.

Authors:  Alex Aleshin; Peter L Greenberg
Journal:  Blood Adv       Date:  2018-10-23

9.  Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.

Authors:  M Roschewski; M Farooqui; G Aue; F Wilhelm; A Wiestner
Journal:  Leukemia       Date:  2013-03-14       Impact factor: 11.528

10.  P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.

Authors:  Sunil Iyengar; Andrew Clear; Csaba Bödör; Lenushka Maharaj; Abigail Lee; Maria Calaminici; Janet Matthews; Sameena Iqbal; Rebecca Auer; John Gribben; Simon Joel
Journal:  Blood       Date:  2013-01-22       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.